Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHENA CAR-T in moderate to severe SLE
NCT06373991Phase 1Not yet recruiting
- Sponsor
- EdiGene Inc.
- Start
- Jul 2024
- Primary completion
- Apr 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ET-901 in systemic lupus erythematosus (SLE), sponsored by EdiGene Inc. Primary endpoints: Dose Limiting Toxicity and Safety and Tolerability. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
ET-901
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06373991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06373991.